Video

Dr. Klein on Gene Mutations in Prostate Cancer

Author(s):

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.

The 3-hydroxybutyrate steroid dehydrogenase gene is the master switch for converting precursors to testosterone and dihydrotestosterone into dihydrotestosterone. It has been discovered that some men are born with a single point mutation in that gene that makes their tumors more efficient at making dihydrotestosterone, which is what drives prostate cancer, Klein explains.

There is a clinical correlation that shows that men who are born with that mutation progress to metastatic castrate resistance faster and die at a higher rate than patients who don’t have that mutation.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD